On November 19, 2026 Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, reported it has been awarded a €2.5 million European Innovation Council (EIC) Accelerator grant to advance its lead program, AT-108 into clinical development.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Asgard was one of just 35 companies selected to receive Accelerator grants in the EIC’s latest evaluation round, out of 453 proposals submitted. The EIC Accelerator supports highly innovative European start-ups and SMEs developing breakthrough technologies with significant commercial potential, and provides grant funding of up to €2.5 million. Asgard will use the grant to help accelerate the preparatory work needed to take its lead asset AT-108 into the clinic in 2027.
In addition to the grant support, Asgard is also eligible to receive equity investment from the EIC Fund of up to €10 million, as part of an upcoming financing round.
Cristiana Pires, Co-founder and CEO of Asgard Therapeutics, said: "This €2.5 million EIC Accelerator grant caps a fantastic year for Asgard, in which we have made huge progress on the road to becoming a clinical-stage company. Being selected is not only strong recognition of our pioneering direct cell reprogramming approach and the potential of our lead asset AT-108. It will also help us prepare AT-108 quicker, so we are ready for the clinic and start dosing patients next year. In addition, the grant opens the door to a potential equity investment from the EIC Fund of up to €10 million, as part of a wider financing round."
AT-108 is a first-in-class, off-the-shelf immunotherapy which directly reprograms tumor-resident cells in vivo into antigen-presenting dendritic-like cells, called cDC1-like cells, triggering a powerful and personalized anti-tumor immune response. Initial indications include recurrent/metastatic head and neck squamous cell carcinoma, microsatellite-stable colorectal cancer, and neoadjuvant, locally advanced resectable head and neck squamous cell carcinoma.
Earlier this month, Asgard published a study in Immunity demonstrating induction of cancer-fighting tertiary lymphoid structures across cold and hot tumor types, further building on the potential of its in-vivo direct cell reprogramming approach. Asgard also presented new data at SITC (Free SITC Whitepaper) 2026 establishing a translational biomarker framework for AT-108. These follow advanced preclinical data presented at the ASGCT (Free ASGCT Whitepaper) Annual Meeting in May, showing that AT-108 as monotherapy doubled median survival in checkpoint-refractory animal models, and significantly extended survival and achieved complete tumor regressions when in combination with immune checkpoint blockade.
Together, these findings strengthen the program’s translational foundation as Asgard prepares to advance AT-108 to the clinic.
(Press release, Asgard Therapeutics, NOV 19, 2026, View Source [SID1234674987])